Cortexin vs FGL

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Mimics NCAM-mediated signaling via FGFR (fibroblast growth factor receptor) activation. Stimulates downstream Erk1/2 and PLCγ pathways. Promotes long-term potentiation (LTP) and synaptogenesis.

FGL (EVYVVAENQQGKSKA) is a synthetic 15-amino-acid peptide derived from the fibronectin type III homology domain 2 of the neural cell adhesion molecule (NCAM), designed as a pharmacomimetic agonist of NCAM to activate FGFR-mediated neurotrophic signaling and mimic the synaptogenic and neuroprotective effects of NCAM receptor engagement in the central nervous system. FGL activates downstream FGFR signaling to promote synaptic plasticity, neuronal survival, and spatial learning in preclinical models; rodent studies have demonstrated cognitive-enhancing and anxiolytic effects in aged animals and in models of neurodegeneration, establishing a preclinical rationale for further investigation. No published human clinical trials, pharmacokinetic studies, or safety evaluations of FGL have been indexed in PubMed; the entirety of the evidence base consists of animal and in vitro studies, and no regulatory body has approved or evaluated FGL for any human indication. FGL has no FDA approval or regulatory approval in any jurisdiction; it is a research compound with a defined neurotrophic mechanism and an exclusively preclinical evidence base, and no clinical data exists to inform its pharmacokinetics, safety, or therapeutic utility in humans.